Abstract Background and Objective Evidence indicates that vitamin K antagonists (VKAs)
and oral anticoagulant therapy are under-utilised for stroke prevention in patients with non …

Aims Warfarin, a vitamin K antagonist (VKA), has been the standard of care for stroke
prevention in patients with atrial fibrillation (AF). Aspirin is recommended for low-risk patients …

Background Stroke prevention is the main goal of treating patients with atrial fibrillation (AF).
Vitamin-K antagonists (VKAs) present an effective treatment in stroke prevention, however …

Background Strokes attributed to atrial fibrillation (AF) represent a major cause of adult
disability and a great burden to society and healthcare systems. Objectives Our objective …

Introduction Economic evaluations are becoming increasingly important due to limitations in
economic resources, the expense of many new treatments, the need to allocate health …

ABSTRACT BACKGROUND: Apixaban, an oral anticoagulant for stroke and systemic
embolism prevention in non-valvular atrial fibrillation (NVAF), was superior to warfarin in …

Introduction Atrial fibrillation (AF), one of the major risk factors for stroke, imposing a
substantial burden to the Swedish health care system. Apixaban has demonstrated …

Background: The AVERROES trial name is the following: The Apixaban Versus
Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or …

Abstract Background and Objective Management of non-valvular atrial fibrillation (NVAF)
focuses on the use of anticoagulation to mitigate the risk of stroke. Until recently, vitamin K …

Purpose The purpose of this analysis was to assess the cost-effectiveness of apixaban 5 mg
BID versus high-and low-dose edoxaban (60 mg and 30 mg once daily) as intended starting …